In December 2022, Novozymes announced that it had entered into a merger agreement with Chr. Hansen with approval from the shareholders. Novozymes was earlier reported to be paying US$12.3 billion for Chr. Hansen.
With Chr. Hansen as a leader in microbials, and Novozymes as a leader in enzymes, the merger will create a world-class fermentation company. Uniting the 2 companies will form a combined company which will offer the biological solutions necessary to address global megatrends and meet customer demands to produce more sustainably and efficiently.
Recently, the merger was also given statutory approval by the Chinese State Administration for Market Regulation (SAMR) accelerating the path to completion of the transaction which is expected to be completed by the final quarter of 2023 or early 2024.
